A phase III randomized clinical trial comparing post-transplant cyclophosphamide with calcineurin inhibitors as a GVHD prophylaxis to standard care of methotrexate and calcineurin inhibitors for acute leukemia incorporating patient pharmacogenomic profiling – a personalized medicine approach in allogeneic hematopoietic cell transplantation PMAT

drug protocol number
1- 28/05/2019
drug sponsor
King Faisal Specialist Hospital and Research Centre
drug study
CYCLOPHOSPHAMIDE (ENDOXAN)
drug trial site
KFSH & RC-R
drug status
Ongoing
drug phase